Results 71 to 80 of about 32,586 (241)

EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: MARKERS OF HEMOSTASIS ACTIVATION AND IN-HOSPITAL OUTCOMES

Российский кардиологический журнал, 2015
Current guidelines recommend use of anticoagulants (preferably fondaparinux) until hospital discharge in non-invasively treated patients (pts) with non-ST-segment elevation acute coronary syndrome (NSTEACS).
I. S. Yavelov, A. S. Knyazev, A. B. Dobrovolsky, N. A. Gratsiansky   +3 more
doaj   +1 more source

Improvement of Hemocompatibility in Passive Cardiovascular Implant Devices

Advanced Therapeutics, Volume 8, Issue 12, December 2025.
With the ever‐increasing reliance on cardiovascular devices and implants, minimizing their impact on blood is vital for their continued success. This review investigates the common methods of tackling this challenge through careful selections of material and surface modifications.
Shiyen L. Perera, Christoph E. Hagemeyer, Julian A. Smith, Josie Carberry, Be'eri Niego   +4 more
wiley   +1 more source

Parenteral anticoagulants in the treatment of acute coronary syndrome: what modern clinical guidelines say

Атеротромбоз, 2022
Parenteral administration of high (therapeutic) doses of anticoagulants is a mandatory component of the initial treatment of acute coronary syndrome (ACS) unless contraindicated.
I. S. Yavelov
doaj   +1 more source

Quantifying Patient Reported and Documented Compliance with Adjuncts to Venous Thromboembolism Prophylaxis [PDF]

, 2017
Objectives: 1. Measure patient compliance with pharmacologic, mechanical and ambulatory prophylactic measures. 2. Evaluate for agreement between nursing documentation and patient reported compliance with mechanical and ambulatory prophylactic measures ...
Bauer, MD, Tyler M., Beck, Johanna, Cowan, MD, Scott W., Dukleska, MD, Katerina, Dworkin, Myles, Johnson, MD, MPH, Adam P., Merli, MD, Geno J, Patel, RN, Kamini D.   +7 more
core   +1 more source

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Arquivos Brasileiros de Cardiologia, 2016
Background: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction.
Alexandre de Matos Soeiro, Pedro Gabriel Melo de Barros e Silva, Eduardo Alberto de Castro Roque, Aline Siqueira Bossa, Maria Cristina César, Sheila Aparecida Simões, Mariana Yumi Okada, Tatiana de Carvalho Andreucci Torres Leal, Fátima Cristina Monteiro Pedroti, Múcio Tavares de Oliveira Jr.   +9 more
doaj   +1 more source

Diagnóstico y tratamiento de la trombosis venosa profunda [PDF]

, 2007
Deep-vein thrombosis (DVT) is a common condition that can lead to complications such as postphlebitic syndrome, pulmonary embolism and death. Currently, an algorithm strategy combining pretest probability, D-dimer testing and compression ultrasonography ...
Garcia, R. (R.), Lecumberri, R. (Ramón), Paramo, J.A. (José Antonio), Rodriguez, P. (P.), Ruiz-de-Gaona, E. (Estefanía)   +4 more
core  

Safety and efficacy of enoxaparin versus unfractionated heparins in conservatively managed patients with acute coronary syndrome: a systematic review

Journal of Pharmacy Practice and Research, Volume 55, Issue 6, Page 447-457, December 2025.
Abstract Aim Guidelines recommend initial anticoagulant management of acute coronary syndrome (ACS) with low molecular weight heparin (LMWH) such as enoxaparin or unfractionated heparin (UFH). Systematic reviews evaluate early trials in the context of multiple other medications or during percutaneous coronary intervention (PCI) only.
Krishna Doshi, Mark Jones, Laetitia Hattingh   +2 more
wiley   +1 more source

Clinical experience with fondaparinux in antiaggregate patients undergoing total hip and knee arthroplasty

Italian Journal of Medicine, 2013
Patients undergoing total hip arthroplasty or total knee arthroplasty have a high risk for post-operative venous thromboembolism. The current study addressed the use of fondaparinux post-operatively in 556 patients with antiplatelet therapy in order to ...
Guido Grappiolo, Marco Scardino, Giuseppe Mazziotta, Stefano Quaini, Corrado Lodigiani, Matteo Carlo Ferrari   +5 more
doaj   +1 more source

Prevention of venous thromboembolism after hip and knee replacement among older adults [PDF]

, 2017
BACKGROUND: Venous thromboembolism (VTE) after total hip and knee replacement is a major patient safety threat, and pharmacologic prophylaxis is generally recommended. However, clinicians disagree on the optimal prophylaxis agent.
Ko, Darae
core  

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source